44
Participants
Start Date
December 20, 2017
Primary Completion Date
July 31, 2026
Study Completion Date
December 31, 2026
Anastrozole
1 mg orally daily, day 1 to day 28
Palbociclib
Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
Trastuzumab
8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
Pertuzumab
840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
Mount Sinai Beth Israel Comprehensive Cancer Center West, New York
Perlmutter Cancer Center NYU Langone, New York
Mount Sinai West, New York
New York Presbyterian Columbia Irving Comprehensive Cancer Center, New York
New York Presbyterian Weill Cornell Medical Center, New York
Herbert Irving Comprehensive Cancer Center
OTHER
Weill Medical College of Cornell University
OTHER
NYU Langone Health
OTHER
Icahn School of Medicine at Mount Sinai
OTHER